Relationship between the Matrix Metalloproteinases (MMPs) levels and lung mechanic parameters established by impulse oscillometry (IOS) in patients with pulmonary tuberculosis (TB) Source: Virtual Congress 2020 – Tuberculosis and comorbidities Year: 2020
Matrix metalloproteinases (MMPs) and acute phase proteins (APP) in predicting the efficacy of intensive phase treatment (IPP) in patients with pulmonary tuberculosis (PT) Source: International Congress 2016 – Treatment management options and costs: vitamin D, Matrix metalloproteinases (MMPs), nutrition, and human genetics Year: 2016
Matrix metalloproteinases (MMPs) and angiogenesis in lung tissue remodeling in different variants of idiopathic interstitial pneumonia (IIP) Source: Eur Respir J 2007; 30: Suppl. 51, 137s Year: 2007
Matrix metalloproteinases (MMPs), tissue inhibitor of matrix metalloproteinases (TIMPs) and transforming growth factor-β (TGFβ) expression in small airways (SA) of usual idiopathic pneumonia (UIP), non-specific interstitial pneumonia (NSIP), hip Source: Annual Congress 2007 - Role of genomics and biological tools in the work-up of interstitial lung disease Year: 2007
Matrix metalloproteinase (MMP) 12 is associated with clinical parameters of disease severity and exacerbations in asthma Source: Annual Congress 2010 - Asthma: basic science and clinical studies Year: 2010
Matrix metalloproteinases and lung disease severity in chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2001; 18: Suppl. 33, 249s Year: 2001
Expression of matrix metalloproteinases and TIMP inhibitors in circulation/lung in patients with chronic obstructive pulmonary disease Source: Annual Congress 2012 - Asthma and COPD: understanding through mechanisms Year: 2012
Matrix metalloproteinases, as markers of the severity of idiopathic pulmonary fibrosis Source: International Congress 2019 – Biomarkers of idiopathic interstitial pneumonia Year: 2019
Matrix metalloproteinases in COPD Source: Eur Respir J 2011; 39: 197-209 Year: 2012
Matrix metalloproteinases in COPD Source: Eur Respir J 2012; 39: 197-209 Year: 2012
Effect of recombinant α-1 antitrypsin (rAAT) and TAPI on neutrophil elastase (NE) and matrix metalloproteinase-9 (MMP9) activity in induced sputum (IS) from healthy smokers and patients with chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2003 - Progress on therapy for chronic obstructive pulmonary disease Year: 2003
Matrix metalloproteinases in tuberculosis Source: Eur Respir J 2011; 38: 456-464 Year: 2011
Exocytosis of matrix metalloproteinases (MMPs) by pulmonary and systemic polymorphonuclear neutrophils (PMN) in hospital acquired pneumonia (HAP) Source: Eur Respir J 2002; 20: Suppl. 38, 585s Year: 2002
Matrix metalloproteinase (MMP) 9 is associated with clinical parameters of severity in cystic fibrosis (CF) Source: Annual Congress 2010 - Cystic fibrosis: lung disease and much more Year: 2010
Increased serum concentrations of tissue inhibitor of metalloproteinase-1 in COPD patients Source: Eur Respir J 2005; 25: 885-890 Year: 2005
Matrix metalloproteinase (MMP) 12 is not associated with clinical parameters of severity in cystic fibrosis (CF) Source: Annual Congress 2010 - Cystic fibrosis: lung disease and much more Year: 2010
Circulating matrix metalloproteinase-9 (MMP-9) is associated with the extension of lung disease in patients with active tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 35s Year: 2004
Matrix metalloproteinases and their inhibitors in pulmonary hypertension}, Source: Eur Respir J 2012; 40: 766-782 Year: 2012
Metalloproteinases (MMPs), tissue inhibitors of metalloproteinases (TIMPs) and transforming growth factor (TGFβ) in pleural tuberculosis Source: Annual Congress 2008 - Genetics, immunology and microbiology of tuberculosis Year: 2008
Matrix metalloproteinase 2 expression in distal lung of fatal asthma Source: Eur Respir J 2006; 28: Suppl. 50, 549s Year: 2006